@boulware_dr @JAMA_current How to do a hatchet job in Ivermectin for COVID-19: first, start with a study of mild illness and low risk patients. All should do well, so intervention will show no benefit.
@boulware_dr @JAMA_current Use a modest number of patients, not enough to show significance with small differences.
Use time to symptom resolution, since all are expected to recover. Do not use viral clearance, which would be more likely to give a statistically significant result. Ignore long Covid.
Use time to symptom resolution, since all are expected to recover. Do not use viral clearance, which would be more likely to give a statistically significant result. Ignore long Covid.
@boulware_dr @JAMA_current Whew! Ivermectin showed a trend to benefit, with a shorter time to symptom resolution, fewer deteriorations, fewer needing escalation of care, no deaths. Fortunately, none of these reach statistical significance!
@boulware_dr @JAMA_current So we can therefore report ivermectin as being ineffective, and JAMA will be happy to publish it!
Oh, did I mention that multiple authors head multiple conflicts of interest of receiving money from Big Pharma?
Oh, did I mention that multiple authors head multiple conflicts of interest of receiving money from Big Pharma?
• • •
Missing some Tweet in this thread? You can try to
force a refresh
